LaNua Medical Led MedTech Project Secures €6 million in DTIF Funding

A MedTech project led by (opens in a new window)LaNua Medical, an Irish medtech device start-up and a University College Dublin (UCD) spin-out, has successfully secured €6 million in funding under Call 7 of the (opens in a new window)Disruptive Technologies Innovation Fund (DTIF). 

The ECORE project, a collaboration by LaNua Medical with Integer Holdings and UCD, will focus on developing and clinically validating an embolisation device that swiftly blocks blood flow and facilitates distal delivery of other embolics or targeted therapies for vascular disorders and cancers, improving safety and effectiveness of procedures.

The DTIF is a €500 million fund, established under the National Development Plan, is managed by the Department of Enterprise, Tourism and Employment with administrative support from Enterprise Ireland. 

The purpose of the Fund is to drive collaboration between Ireland’s world-class research base and industry as well as facilitating enterprises to compete directly for funding in support of the development and adoption of these technologies. The aim is to support investment in the development and deployment of disruptive technologies and applications on a commercial basis.

The ECORE project was one of eight projects which are receiving a total of €33.1 million in DTIF funding which have been announced by Minister for Enterprise, Tourism and Employment, Peter Burke, and Minister for Further and Higher Education, Research, Innovation and Science, James Lawless.

Dr Cormac Farrelly, Interventional Radiologist, Mater Misericordiae University Hospital, and a co-founder and CMO, LaNua Medical, said, “This represents another important milestone for LaNua Medical. The funding provides a real boost to this already exciting project and will enable more effective collaboration between ourselves, UCD and Integer Holdings.  It will accelerate the development and validation of our technology to be effective across a large range of sizes and different blood vessel types." 

Pictured (l-r) at UCD are; Denis Nolan, CTO, LaNua Medical; Tom Fitzmaurice, CEO, LaNua Medical; Dr Cormac Farrelly, Interventional Radiologist, Mater Misericordiae University Hospital, co-founder and CMO, LaNua Medical; Dr Sajjad Amiri, co-founder, LaNua Medical and Dr Eoin O'Cearbhaill, UCD School of Mechanical and Materials Engineering and co-founder, LaNua Medical. (Credit - Paul Sharp/Sharppix).

The UCD researchers who will be working on the ECORE project include, Dr Eoin O'Cearbhaill, Professor Aisling Ní Annaidh, Professor Philip Cardiff and Associate Professor Mert Celikin of the UCD School of Mechanical and Materials Engineering and the UCD Centre for Biomedical Engineering.

Dr Eoin O'Cearbhaill, said, “The UCD School of Mechanical and Materials Engineering and the UCD Centre for Biomedical Engineering are very grateful for this opportunity to support LaNua Medical's development of disruptive endovascular embolisation devices as part of this exciting DTIF funded project.”

Minister Peter Burke TD said, “Today’s investment through the Disruptive Technologies Innovation Fund positions Ireland at the forefront of emerging technologies, securing strategic advantage in both existing and future markets. By backing innovations in med-tech, life sciences, and sustainable data infrastructure, we are strengthening our healthcare system, reducing environmental impact, and enhancing economic resilience.”

Jenny Melia, CEO, Enterprise Ireland, “Enterprise Ireland is proud to support the Disruptive Technologies Innovation Fund, which is driving collaboration between SMEs, multinationals and our world-class research base. The projects announced today highlight the strength of Irish innovation in areas such as healthcare, sustainability and advanced manufacturing. By backing these ambitious collaborations, we are enabling companies to develop and commercialise cutting-edge technologies with the potential to transform lives, create new markets and deliver real economic impact for Ireland.”

Minister James Lawless TD said, “We are pleased to announce the approval of eight additional projects under the Disruptive Technologies Innovation Fund (DTIF). With 118 projects now supported, this initiative continues to drive transformative change through cutting-edge technologies. These projects will not only deliver innovative solutions that benefit our citizens, but also contribute to the growth of Ireland’s knowledge economy by creating highly specialised, future-focused roles for our graduates.”

LaNua Medical, founded in 2024 with the support of NovaUCD, is developing a groundbreaking technology that makes it easy, safe, and cheaper for doctors to treat internal bleeding, vascular malformations and many benign and malignant tumours.

The company, which was co-founded by Dr Farrelly and Tom Fitzmaurice with Dr O'Cearbhaill and Dr Sajjad Amiri, raised €6 million in seed funding in 2024. This funding round was co-led by Elkstone and Atlantic Bridge, with participation from Enterprise Ireland and Furthr VC.

ENDS

30 September 2025

For further information contact Micéal Whelan, Communications and Media Relations Manager, UCD Research and Innovation, NovaUCD, e: (opens in a new window)miceal.whelan@ucd.ie.

Editors Notes

DTIF Call 7 applications are assessed by panels of international experts against four criteria, quality of the disruptive technology, excellence of overall approach, economic impact and sustainability, and strength of the collaboration.

To date, a total of €421 million has been allocated to 110 projects consisting of 413 collaborative partners across seven DTIF Calls. These eight projects will bring the total funding awarded to €455 million across 118 projects.  

Prospective applicants can obtain detailed information on the fund and on the application process through (opens in a new window)enterprise.gov.ie/DTIF.